- Home
- RELI vs BPTH Comparison
RELI vs BPTH Comparison
Compare RELI & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELI
- BPTH
- Stock Information
- Founded
- RELI 2013
- BPTH 2007
- Country
- RELI United States
- BPTH United States
- Employees
- RELI N/A
- BPTH N/A
- Industry
- RELI Specialty Insurers
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- RELI Finance
- BPTH Health Care
- Exchange
- RELI Nasdaq
- BPTH Nasdaq
- Market Cap
- RELI 2.5M
- BPTH 2.8M
- IPO Year
- RELI N/A
- BPTH N/A
- Fundamental
- Price
- RELI $1.24
- BPTH $0.67
- Analyst Decision
- RELI Strong Buy
- BPTH Strong Buy
- Analyst Count
- RELI 1
- BPTH 2
- Target Price
- RELI $119.00
- BPTH $30.00
- AVG Volume (30 Days)
- RELI 225.5K
- BPTH 107.0K
- Earning Date
- RELI 11-07-2024
- BPTH 11-15-2024
- Dividend Yield
- RELI N/A
- BPTH N/A
- EPS Growth
- RELI N/A
- BPTH N/A
- EPS
- RELI N/A
- BPTH N/A
- Revenue
- RELI $14,078,473.00
- BPTH N/A
- Revenue This Year
- RELI N/A
- BPTH N/A
- Revenue Next Year
- RELI N/A
- BPTH N/A
- P/E Ratio
- RELI N/A
- BPTH N/A
- Revenue Growth
- RELI 4.71
- BPTH N/A
- 52 Week Low
- RELI $1.20
- BPTH $0.59
- 52 Week High
- RELI $18.53
- BPTH $12.00
- Technical
- Relative Strength Index (RSI)
- RELI 31.68
- BPTH 39.07
- Support Level
- RELI $1.28
- BPTH $0.64
- Resistance Level
- RELI $1.66
- BPTH $0.90
- Average True Range (ATR)
- RELI 0.15
- BPTH 0.10
- MACD
- RELI -0.00
- BPTH 0.01
- Stochastic Oscillator
- RELI 0.00
- BPTH 25.48
About RELI Reliance Global Group Inc.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing an acquisition strategy, initially and primarily focused on wholesale and retail insurance agencies. Its primary strategy is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.